The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer (Q27682565)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Ryohei Katayama

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Adam S Crystal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Nanxin Li

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Christian C Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Justin F Gainor

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Pierre-Yves Michellys

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Mark M Awad

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Noriko Yanagitani

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Sungjoon Kim

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

AnneMarie C Pferdekamper

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Jie Li

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Shailaja Kasibhatla

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Frank Sun

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Xiuying Sun

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Su Hua

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Peter McNamara

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Sidra Mahmood

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Elizabeth L Lockerman

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Naoya Fujita

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Makoto Nishio

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Jennifer L Harris

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Alice T Shaw

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Jeffrey A Engelman

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

publication date

June 2014

0 references

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

662-673

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

11 June 2020

0 references

0 references

0 references

0 references

0 references

0 references

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

Ceritinib in ALK-rearranged non-small-cell lung cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068971

10.1158/2159-8290.CD-13-0846

27 November 2018

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24675041%20AND%20SRC:MED&resulttype=core&format=json